Successively, several approaches to nanoparticle formulations have been developed that take advantage of the CD44-targeting properties of HA, including the chemical conjugation of HA to pre-formed lipid-based nanocarriers, for the active targeting of small or large active molecules for the treatment of cancer [59], and self-assembling nanosystems for targeted siRNA delivery [60]. Here, CD44 is linked to cancer.